A biobank of colorectal cancer patient-derived xenografts

14Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.

Abstract

Colorectal cancer (CRC) is a challenging disease, with a high mortality rate and limited effective treatment options, particularly for late-stage disease. Patient-derived xenografts (PDXs) have emerged as an informative, renewable experimental resource to model CRC architecture and biology. Here, we describe the generation of a biobank of CRC PDXs from stage I to stage IV patients. We demonstrate that PDXs within our biobank recapitulate the histopathological and mutation features of the original patient tumor. In addition, we demonstrate the utility of this resource in pre-clinical chemotherapy and targeted treatment studies, highlighting the translational potential of PDX models in the identification of new therapies that will improve the overall survival of CRC patients.

Cite

CITATION STYLE

APA

Abdirahman, S. M., Christie, M., Preaudet, A., Burstroem, M. C. U., Mouradov, D., Lee, B., … Putoczki, T. L. (2020). A biobank of colorectal cancer patient-derived xenografts. Cancers, 12(9), 1–19. https://doi.org/10.3390/cancers12092340

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free